Sathana Boonyapipat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sathana Boonyapipat has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Nungrutai Saeaib
Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
3 shared publicationsKulisara Nanthamongkolkul
Department of Obstetrics and Gynecology, Faculty of Medicine; Prince of Songkla University; Songkhla Thailand
2 shared publicationsTippawan Liabsuetrakul
Department of Epidemiology, Faculty of Medicine; Prince of Songkla University; Songkhla Thailand
2 shared publications- Ingporn Jiamset
Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
1 shared publication - Krantarat Peeyananjarassri
Department of Obstetrics and Gynecology, Faculty of Medicine Prince of Songkla University Songkhla Thailand
1 shared publication - Kulisara Nanthamongkolkul
Department of Obstetrics and Gynecology, Faculty of Medicine Prince of Songkla University Songkhla Thailand
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 65 (4) , 774-781
Pretreatment systemic immune-inflammatory index (SII) for a prognostic impact in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
- 26 June 2026
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 65 (4) , 774-781
Open AccessPretreatment systemic immune-inflammatory index (SII) for a prognostic impact in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
- 23 September 2024
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2024 (9) , CD014755
Fertility-sparing surgical interventions for low-risk, non-metastatic gestational trophoblastic neoplasia
Background The primary treatment approach for addressing low‐risk nonmetastatic gestational trophoblastic neoplasia (LR‐NMGTN) in women desiring fertility preservation involves chemotherapy. An alternative option for treatment is fertility‐sparing surgical interventions, either alone or in combination with adjuvant chemotherapy. The hypothesised advantages of choosing fertility‐sparing surgery in cases of LR‐NMGTN include potential avoidance of adverse effects associated with chemotherapy, potential reduction in the number of chemotherapy cycles required to achieve complete remission, and potential reduction in time to remission. Objectives To measure the benefits and harms of fertility‐sparing surgical interventions, with or without adjuvant chemotherapy, compared to primary chemotherapy alone, for the treatment of women with low‐risk, non‐metastatic gestational trophoblastic neoplasia (LR‐NMGTN). Search methods We searched CENTRAL, MEDLINE, Embase, Web of Science, ClinicalTrials.gov and WHO ICTRP on 31 January 2024. We also searched abstracts of scientific meetings and reference lists of included studies. Selection criteria We included all randomised controlled trials (RCTs) comparing fertility‐sparing surgical interventions, with or without subsequent adjuvant chemotherapy, versus primary chemotherapy as standard care for the treatment of women with LR‐NMGTN. Data collection and analysis We employed standard Cochrane methodological procedures. We used the GRADE approach to assess the certainty of evidence for each outcome, if available. We focused on the following outcomes: treatment success rate, relapse, disease‐specific mortality, death due to treatment, pregnancy rate, quality of life, and any adverse events. Main results We included two RCTs, with a total of 151 participants contributing data to our analyses. Both studies used uterine curettage as the fertility‐sparing surgical intervention. Fertility‐sparing surgical intervention without subsequent adjuvant chemotherapy versus primary chemotherapy alone One RCT involving 62 participants with varying hCG (human chorionic gonadotrophin) levels evaluated this comparison. Most of our outcomes of interest were not measured in this study. The relative risk of experiencing any adverse event could not be estimated as chemotherapy adverse effects were not reported. The study reported that there were no surgical complications. Chemotherapy was administered to 50% of participants in the intervention group after curettage because their hCG levels increased. Fertility‐sparing surgical intervention with subsequent adjuvant chemotherapy versus primary chemotherapy alone One RCT involving 89 participants with hCG levels < 5000 IU/L evaluated this comparison. We judged the risk of bias in the study to be high. The evidence was very uncertain about the effect of uterine curettage with subsequent adjuvant chemotherapy on treatment success rate (RR 1.03, 95% CI 0.86 to1.23; 86 participants), relapse (RR 0.5, 95% CI 0.05 to 5.31; 86 participants), pregnancy rate (RR 0.86, 95% CI 0.31 to 2.34; 86 participants), and rate of adverse events (RR 1.15, 95% CI 0.63 to 2.13; 86 participants), all very low certainty evidence. The relative risks of disease‐specific mortality and death due to treatment could not be estimated as there were no deaths in either group. There were no results for quality of life as this outcome was not reported. Authors' conclusions Uterine curettage is the only fertility‐sparing surgical intervention for LR‐NMGTN that has been evaluated in a randomised controlled trial. The evidence is very uncertain about the benefits and harms of uterine curettage, with or without subsequent adjuvant chemotherapy, compared to primary chemotherapy alone. The two available studies are small with a high risk of bias, and future research may find substantially different results for all reported outcomes. Larger RCTs, with appropriate clinical outcome measures, would be required to determine the benefits or harms of fertility‐sparing surgical interventions for this population.
- 23 September 2024
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2024 (9) , CD014755
Fertility-sparing surgical interventions for low-risk, non-metastatic gestational trophoblastic neoplasia
Background The primary treatment approach for addressing low‐risk nonmetastatic gestational trophoblastic neoplasia (LR‐NMGTN) in women desiring fertility preservation involves chemotherapy. An alternative option for treatment is fertility‐sparing surgical interventions, either alone or in combination with adjuvant chemotherapy. The hypothesised advantages of choosing fertility‐sparing surgery in cases of LR‐NMGTN include potential avoidance of adverse effects associated with chemotherapy, potential reduction in the number of chemotherapy cycles required to achieve complete remission, and potential reduction in time to remission. Objectives To measure the benefits and harms of fertility‐sparing surgical interventions, with or without adjuvant chemotherapy, compared to primary chemotherapy alone, for the treatment of women with low‐risk, non‐metastatic gestational trophoblastic neoplasia (LR‐NMGTN). Search methods We searched CENTRAL, MEDLINE, Embase, Web of Science, ClinicalTrials.gov and WHO ICTRP on 31 January 2024. We also searched abstracts of scientific meetings and reference lists of included studies. Selection criteria We included all randomised controlled trials (RCTs) comparing fertility‐sparing surgical interventions, with or without subsequent adjuvant chemotherapy, versus primary chemotherapy as standard care for the treatment of women with LR‐NMGTN. Data collection and analysis We employed standard Cochrane methodological procedures. We used the GRADE approach to assess the certainty of evidence for each outcome, if available. We focused on the following outcomes: treatment success rate, relapse, disease‐specific mortality, death due to treatment, pregnancy rate, quality of life, and any adverse events. Main results We included two RCTs, with a total of 151 participants contributing data to our analyses. Both studies used uterine curettage as the fertility‐sparing surgical intervention. Fertility‐sparing surgical intervention without subsequent adjuvant chemotherapy versus primary chemotherapy alone One RCT involving 62 participants with varying hCG (human chorionic gonadotrophin) levels evaluated this comparison. Most of our outcomes of interest were not measured in this study. The relative risk of experiencing any adverse event could not be estimated as chemotherapy adverse effects were not reported. The study reported that there were no surgical complications. Chemotherapy was administered to 50% of participants in the intervention group after curettage because their hCG levels increased. Fertility‐sparing surgical intervention with subsequent adjuvant chemotherapy versus primary chemotherapy alone One RCT involving 89 participants with hCG levels < 5000 IU/L evaluated this comparison. We judged the risk of bias in the study to be high. The evidence was very uncertain about the effect of uterine curettage with subsequent adjuvant chemotherapy on treatment success rate (RR 1.03, 95% CI 0.86 to1.23; 86 participants), relapse (RR 0.5, 95% CI 0.05 to 5.31; 86 participants), pregnancy rate (RR 0.86, 95% CI 0.31 to 2.34; 86 participants), and rate of adverse events (RR 1.15, 95% CI 0.63 to 2.13; 86 participants), all very low certainty evidence. The relative risks of disease‐specific mortality and death due to treatment could not be estimated as there were no deaths in either group. There were no results for quality of life as this outcome was not reported. Authors' conclusions Uterine curettage is the only fertility‐sparing surgical intervention for LR‐NMGTN that has been evaluated in a randomised controlled trial. The evidence is very uncertain about the benefits and harms of uterine curettage, with or without subsequent adjuvant chemotherapy, compared to primary chemotherapy alone. The two available studies are small with a high risk of bias, and future research may find substantially different results for all reported outcomes. Larger RCTs, with appropriate clinical outcome measures, would be required to determine the benefits or harms of fertility‐sparing surgical interventions for this population.
- Open Access
- 5 April 2023
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 20 (1) , 363-368
Epithelial ovarian cancer in younger age versus older age groups: Survival and clinicopathological features
Objectives: This study aimed to analyze the survivals and clinicopathological features of epithelial ovarian cancer (EOC) in younger age patients and to determine the impact of age on survival. Methods: EOC patients aged ≤40 years were matched to patients aged >40 years at a 1:4 ratio. Disease-specific survival (DSS), progression-free survival (PFS), and clinicopathological and treatment features were compared between patients aged ≤40 and >40 years. Results: A total of 763 EOC patients were reviewed. During a median follow-up period of 41 (range, 1–195) months, EOC patients aged ≤40 and >40 years did not show any statistically significant difference in median DSS (120 versusversus 84.7 months; hazard ratio, 0.78; 95% confidence interval, 0.58, 1.06); however, the median PFS was better in patients aged ≤40 years (median PFS not reached versusversus 41 months; HR, 0.65; 95% CI, 0.5, 0.85). Age ≤40 years was an independent favorable prognostic factor for DSS at 3 years after diagnosis. In contrast, younger age was an independent poor prognostic factor prior to this time point. EOC patients aged ≤40 years exhibited a significantly higher rate of early-stage disease, a higher proportion of mucinous subtype, and lower cancer antigen-125 level. Conclusion: Overall, EOC patients in the younger age group were associated with more favorable prognostic factors and showed better PFS, but not DSS, than those in the older age group. Younger age was identified as an unfavorable prognostic factor within 3 years of diagnosis and became a favorable prognostic factor after 3 years.
- 5 April 2023
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 20 (1) , 363-368
Open AccessEpithelial ovarian cancer in younger age versus older age groups: Survival and clinicopathological features
Objectives: This study aimed to analyze the survivals and clinicopathological features of epithelial ovarian cancer (EOC) in younger age patients and to determine the impact of age on survival. Methods: EOC patients aged ≤40 years were matched to patients aged >40 years at a 1:4 ratio. Disease-specific survival (DSS), progression-free survival (PFS), and clinicopathological and treatment features were compared between patients aged ≤40 and >40 years. Results: A total of 763 EOC patients were reviewed. During a median follow-up period of 41 (range, 1–195) months, EOC patients aged ≤40 and >40 years did not show any statistically significant difference in median DSS (120 versusversus 84.7 months; hazard ratio, 0.78; 95% confidence interval, 0.58, 1.06); however, the median PFS was better in patients aged ≤40 years (median PFS not reached versusversus 41 months; HR, 0.65; 95% CI, 0.5, 0.85). Age ≤40 years was an independent favorable prognostic factor for DSS at 3 years after diagnosis. In contrast, younger age was an independent poor prognostic factor prior to this time point. EOC patients aged ≤40 years exhibited a significantly higher rate of early-stage disease, a higher proportion of mucinous subtype, and lower cancer antigen-125 level. Conclusion: Overall, EOC patients in the younger age group were associated with more favorable prognostic factors and showed better PFS, but not DSS, than those in the older age group. Younger age was identified as an unfavorable prognostic factor within 3 years of diagnosis and became a favorable prognostic factor after 3 years.
- 7 February 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 162 (1) , 317-324
Impact of appendectomy of a grossly normal appendix on the survival outcomes of mucinous ovarian carcinomas in a tertiary hospital
Objective: To evaluate the survival outcomes of appendectomy for a grossly normal appendix in patients with mucinous ovarian carcinomas.Methods: Retrospective cohort study. Patients with mucinous ovarian carcinomas with grossly normal appendices who underwent primary surgery between 2002 and 2022 were enrolled. The overall survival (OS) and progression‐free survival (PFS) of appendectomy and non‐appendectomy groups were analyzed using the Kaplan–Meier method and compared using the log‐rank test. Univariate and multivariate Cox regression analyses were used to determine the independent factors associated with OS and PFS.Results: Of 192 patients, appendectomy was performed in 138 (71.9%). Three (1.6%) patients had primary appendiceal tumors and two (1.0%) had appendiceal metastases of ovarian origin. The median follow‐up time was 68.8 months. The OS and PFS were better in patients in the appendectomy group than in those in the non‐appendectomy group (5‐year OS: 80.72% vs. 65.05%, P = 0.012; 5‐year PFS: 76.32% vs. 58.60%, P = 0.020). Independent factors associated with poor OS and PFS were no omentectomy, peritoneal seeding, and advanced International Federation of Gynecology and Obstetrics (FIGO) stage.Conclusion: Appendectomy of a grossly normal appendix was not an independent prognostic factor for OS and PFS in patients with mucinous ovarian carcinomas.
- 7 February 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 162 (1) , 317-324
Impact of appendectomy of a grossly normal appendix on the survival outcomes of mucinous ovarian carcinomas in a tertiary hospital
Objective: To evaluate the survival outcomes of appendectomy for a grossly normal appendix in patients with mucinous ovarian carcinomas.Methods: Retrospective cohort study. Patients with mucinous ovarian carcinomas with grossly normal appendices who underwent primary surgery between 2002 and 2022 were enrolled. The overall survival (OS) and progression‐free survival (PFS) of appendectomy and non‐appendectomy groups were analyzed using the Kaplan–Meier method and compared using the log‐rank test. Univariate and multivariate Cox regression analyses were used to determine the independent factors associated with OS and PFS.Results: Of 192 patients, appendectomy was performed in 138 (71.9%). Three (1.6%) patients had primary appendiceal tumors and two (1.0%) had appendiceal metastases of ovarian origin. The median follow‐up time was 68.8 months. The OS and PFS were better in patients in the appendectomy group than in those in the non‐appendectomy group (5‐year OS: 80.72% vs. 65.05%, P = 0.012; 5‐year PFS: 76.32% vs. 58.60%, P = 0.020). Independent factors associated with poor OS and PFS were no omentectomy, peritoneal seeding, and advanced International Federation of Gynecology and Obstetrics (FIGO) stage.Conclusion: Appendectomy of a grossly normal appendix was not an independent prognostic factor for OS and PFS in patients with mucinous ovarian carcinomas.
- 13 October 2022
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2022 (10)
Fertility-sparing, surgical interventions for low-risk, non-metastatic gestational trophoblastic neoplasia
- 13 October 2022
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2022 (10)
Fertility-sparing, surgical interventions for low-risk, non-metastatic gestational trophoblastic neoplasia
- Open Access
- 20 July 2022
- Published by Wiley in Health Science Reports
- Vol. 5 (4) , e729
Serum human chorionic gonadotropin ratios for the detection of etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance in high‐risk gestational trophoblastic neoplasia
Aims: This study aimed to identify the optimal human chorionic gonadotropin (hCG) ratio in predicting etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance in women diagnosed with high‐risk gestational trophoblastic neoplasia (GTN) and to compare the chemoresistant disease detection rate by using the optimal hCG ratio and traditional criteria.Methods: Seventy‐six women with primary high‐risk GTN treated with etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine in a tertiary‐care center were included. The hCG ratio was determined by its serum pretreatment level divided by that before each cycle of chemotherapy. The traditional criteria for chemoresistance included plateau or rising of hCG or presence of new metastasis. The optimal hCG ratio was determined using receiver operating characteristics (ROC) curve analysis.Results: Among the specificities of 90%, 92.5%, and 95%, the 90% specificity yielded the best ROC curve. At 90% specificity, the best area under curve value was at the fourth cycle with 75% sensitivity. The hCG ratio at the fourth cycle was 31.92. Using the ratio at the fourth cycle, chemoresistant disease was detected in six out of eight patients, compared to one in the traditional criteria. When combining the two diagnostic tools, the cumulative detection rate in the fourth cycle was 10/12 (83.3%) of total drug resistance. Among patients who developed drug resistance at the fourth cycle or thereafter, the use of the ratio at the fourth cycle could diagnose chemoresistance approximately two cycles earlier than that with the traditional criteria.Conclusions: A hCG ratio of <31.9 at the fourth cycle should be considered a high‐risk for etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance and may need second‐line chemotherapy. The ratio increases the detection rate of resistance to these drugs more than the traditional criteria.
- 20 July 2022
- Published by Wiley in Health Science Reports
- Vol. 5 (4) , e729
Open AccessSerum human chorionic gonadotropin ratios for the detection of etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance in high‐risk gestational trophoblastic neoplasia
Aims: This study aimed to identify the optimal human chorionic gonadotropin (hCG) ratio in predicting etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance in women diagnosed with high‐risk gestational trophoblastic neoplasia (GTN) and to compare the chemoresistant disease detection rate by using the optimal hCG ratio and traditional criteria.Methods: Seventy‐six women with primary high‐risk GTN treated with etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine in a tertiary‐care center were included. The hCG ratio was determined by its serum pretreatment level divided by that before each cycle of chemotherapy. The traditional criteria for chemoresistance included plateau or rising of hCG or presence of new metastasis. The optimal hCG ratio was determined using receiver operating characteristics (ROC) curve analysis.Results: Among the specificities of 90%, 92.5%, and 95%, the 90% specificity yielded the best ROC curve. At 90% specificity, the best area under curve value was at the fourth cycle with 75% sensitivity. The hCG ratio at the fourth cycle was 31.92. Using the ratio at the fourth cycle, chemoresistant disease was detected in six out of eight patients, compared to one in the traditional criteria. When combining the two diagnostic tools, the cumulative detection rate in the fourth cycle was 10/12 (83.3%) of total drug resistance. Among patients who developed drug resistance at the fourth cycle or thereafter, the use of the ratio at the fourth cycle could diagnose chemoresistance approximately two cycles earlier than that with the traditional criteria.Conclusions: A hCG ratio of <31.9 at the fourth cycle should be considered a high‐risk for etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance and may need second‐line chemotherapy. The ratio increases the detection rate of resistance to these drugs more than the traditional criteria.